Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis

Table 2 Demographic data of studies comparing thymectomy with conservative treatment in late-onset NTMG

Author/year/coconut	Study design	Study period	Follow-up (y) (mean/range)	Age (y) (cutoff/range)	Thymectomy (events/all)		Conservative (events/all)		Thymic histology hyperplasia/involution/normal	Anti-AChR-ab(+/−)	Preoperative classification	Surgical procedures	Medical treatment	NOS score
Author/year/coconut	Study design	Study period	Follow-up (y) (mean/range)	Age (y) (cutoff/range)	CSR	PR	CSR	PR	Thymic histology hyperplasia/involution/normal	Anti-AChR-ab(+/−)	Preoperative classification	Surgical procedures	Medical treatment	NOS score
Kim/2019/South Korea [15]	Single-center retrospective	1990–2018	NA/2.5–11	45 (onset) 50 (thy)*/47.8–66	6/34	18/34	20/105	28/105	18/16/0	139/0	II 57/III 52/IV 8/V 22 MGFA	NA	Anticholinesterase; corticosteroid; immuno-suppressant	9
Romi/2002/Norway [11]	Single-center retrospective	1969–1999	NA/2–5	50/NA	4/21	2/21	3/22	4/22	0/21/0	43/0	Mean 2.9 for thymectomy,2.6 for conservative group. Osserman	TS	Corticosteroid; immuno-suppressant	9
Kawaguchi/2007/Japan (13)	Multicenter retrospective	1999–2000	9.6/NA	50/50–78	6/20		3/14		NA	29/5	Mean 2 for thymectomy,2.5 for conservative group. MGFA	NA	Anticholinesterase; corticosteroid; immuno-suppressant	8

NTMG non-thymomatous myasthenia gravis, Anti–AChR-ab anti-acetylcholine receptor antibody, CSR complete stable remission, PR pharmacological remission, TS trans-sternal thymectomy, MGFA Myasthenia Gravis Foundation of America, NA not available, NOS Newcastle–Ottawa scale
*Onset of MG at ≥ 45 years of age/when patient underwent thymectomy at ≥ 50 years of age

ISSN: 1750-1172